Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Recruiting Phase 2 Interventional Study
Migraine With Aura
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nice · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading de…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of migraine with aura code * At least 1 aura with aura per month in the 3 months prior to inclusion * No prophylactic antimigraine treatment for at least 1 month prior to inclusion * For women of childbearing age, use of a reliable contraceptive method at least 3 mon…
Contacts

Michel LANTERI-MINET, Dr

04 92 03 76 46

lanteri-minet.m@chu-nice.fr

CONTACT

sylvie ROMETTINO

romettino.s@chu-nice.fr

CONTACT